Advanced Filters
noise

Dermatitis, Atopic Clinical Trials

A listing of Dermatitis, Atopic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 167 clinical trials
M Meng-Che Lu

Prebiotic Effects of Mulberry Fruit in Children and Adolescents With Atopic Dermatitis

This project proposes a randomized controlled human study to explore the prebiotic effects of consuming mulberry juice on atopic dermatitis in children and adolescents. The study aims to investigate the potential of mulberry fruit as a human prebiotic. This human study will recruit up to 120 participants from the Taipei …

6 - 17 years of age All Phase N/A
A Aclaris Clinical Operations

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

18 - 70 years of age All Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit …

18 years of age All Phase 2

Effects of an Emollient Containing Postbiotic Saccharomyces and Lactobacillus on Pediatric Atopic Dermatitis

The goal of this study is to investigate whether the use of emollients containing postbiotic Saccharomyces and Lactobacillus can significantly reduce the risk of atopic dermatitis (AD) recurrence in pediatric patients aged 0-6 years during the remission phase, compared to the routine maintenance treatment with conventional emollients.

1 - 6 years of age All Phase N/A

Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week

18 - 75 years of age All Phase 3
Q Qianjin Lu

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis

18 years of age All Phase 3
I Irene García, MD

Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models

This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis that require systemic treatment after failure, intolerance or contraindication to cyclosporine.

years of age All Phase 4
S Study Coordinator

SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes including gene expression, protein degradation, and multiple cellular stress responses. RBN-3143 is a PARP-14 inhibitor. PARP14 is over-expressed in tissues with inflammatory diseases. RBN-3143 is a novel, orally administered PARP14 inhibitor that …

18 - 65 years of age All Phase 1
H H G Berlin, ESQ

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population

12 - 75 years of age All Phase N/A
G Gao Xinghua, MD

Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial to evaluate the efficacy of QLM3003 ointment at week 8 based on the primary endpoint (EASI 75) and key secondary endpoint (IGA-TS).in patients with mild to moderate atopic dermatitis. A total of 360 patients with mild to moderate …

18 - 75 years of age All Phase 3

Simplify language using AI